Cholestasis is a marker for hepatocellular carcinomas displaying β-catenin mutations

Journal of Pathology

Volumn 212, Issue 3, 2007, Pages 345-352

  Audard, V ^a,b,c,d   Grimber, G ^a,b,c,d   Elie, C ^d,e   Radenen, B ^d,e   Audebourg, A ^e   Letourmeur, F ^a,b,c,d   Soubrane, O ^d,e   Vacher Lavenu, M C ^d,e   Perret, C ^a,b,c,d   Cavard, C ^a,b,c,d   Terris, B ^a,b,c,d,e  

^a INSTITUT COCHIN   (France)

^b INSERM   (France)

^c CNRS   (France)

^d Faculté de Médicine René Descartes Paris 5   (France)

^e AP HP ^*  (France)

Author keywords

catenin; Bile acids; Cholestasis ABCG2 BCRP; Claudin2; Glutamine synthetase; Hepatocellular carcinoma

Indexed keywords

BETA CATENIN; GLUTAMATE AMMONIA LIGASE; WNT PROTEIN;

ADULT; AGED; ARTICLE; CHOLESTASIS; CLINICAL FEATURE; CONTROLLED STUDY; DNA SYNTHESIS; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; CHOLESTASIS; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION; GLUTAMATE-AMMONIA LIGASE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; WNT1 PROTEIN;

EID: 34347385893     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2169     Document Type: Article

References (29)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37(Suppl 8):S4-S66.
2. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002;36:S74-S83.
3. Buendia MA. Genetics of hepatocellular carcinoma. Semin Cancer Biol 2000;10:185-200.
4. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nature Genet 2002;31:339-46.
5. Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 2006;25:3778-3786.
6. de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998;95:8847-8851.
7. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001;120:1763-1773.
8. Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002; 21:4863-4871.
9. Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nature Genet 2000;24:245-250.
10. Zucman-Rossi J, Benhamouche S, Godard C, Boyault S, Grimber G, Balabaud C, et al. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene 2007;26:774-780.
11. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003;1653:1-24.
12. Nhieu JT, Renard CA, Wei Y, Cherqui D, Zafrani ES, Buendia MA. Nuclear accumulation of mutated bota-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol 1999; 155:703-710.
13. Cadoret A, Ovejero C, Terris B, Souil E, Levy L, Lamers WH, et al. New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene 2002;21:8293-8301.
14. Levy L, Neuveut C, Renard CA, Charneau P, Branchereau S, Gauthier F, et al. Transcriptional activation of interleukin-8 by beta-catenin-Tcf4. J Biol Chem 2002;277:42386-42393.
15. Yamamoto Y, Sakamoto M, Fujii G, Tsuiji H, Kenetaka K, Asaka M, et al. Overexpression of orphan G-protein-coupled receptor, Gpr49, in human hepatocellular carcinomas with beta-catenin mutations. Hepatology 2003;37:528-533.
16. Ovejero C, Cavard C, Perianin A, Hakvoort T, Vermeulen J, Godard C, et al. Identification of the leokocyte cell-derived chemotaxin 2 as a direct target gene of beta-catenin in the liver. Hepatology 2004;40:167-176.
17. Cavard C, Terris B, Grimber G, Christa L, Audard V, Radenen-Bussiere B, et al. Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primary liver tumors with beta-catenin mutations. Oncogene 2006;25:599-608.
18. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954;7:462-503.
19. Lauwers GY, Terris B, Balis UJ, Batts KP, Regimbeau JM, Chang Y, et al. Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index. Am J Surg Pathol 2002;26:25-34.
20. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-293.
21. Diestra JE, Scheffer GL, Catala I, Maliepaard M, Schellens JH, Scheper RJ, et al. Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 2002;198:213-219.
22. Rahner C, Mitic LL, Anderson JM. Heterogeneity in expression and subcellular localization of claudins 2, 3, 4, and 5 in the rat liver, pancreas, and gut. Gastroenterology 2001;120:411-422.
23. Hsu HC, Jeng YM, Mao TL, Chu JS, Lai PL, Peng SY. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 2000;157:763-770.
24. Terris B, Pineau P, Bregeaud L, Valla D, Belghiti J, Tiollais P, et al. Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas. Oncogene 1999;18:6583-6588.
25. Huang H, Fujii H, Sankila A, Mahler-Araujo BM, Matsuda M, Cathomas G, et al. Beta-catenin mutations are frequent in human hepatocellular carcinomas. Am J Pathol 1999;155:1795-1801.
26. Osada T, Nagashima I, Tsuno NH, Kitayama J, Nagawa H. Prognostic significance of glutamine synthetase expression in unifocal advanced hepatocellular carcinoma. J Hepatol 2000;33:247-253.
27. Zucman-Rossi J, Jeannot E, Nhieu JT, Scoazec JY, Guettier C, Rebouissou S, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006;43:515-524.
28. Mao TL, Chu JS, Jeng YM, Lai PL, Hsu HC. Expression of mutant nuclear beta-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis. J Pathol 2001;193:95-101.
29. Huang W, Ma K, Zhang J, Qatanani M, Cuvillier J, Liu J, et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 2006;312:233-236.